Levels of bioavailable, and free forms of 25(OH)D after supplementation with vitamin D
Bioavailable 25(OH)D
free 25(OH)D
primary hyperparathyroidism
vitamin D-binding protein
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
25
06
2022
accepted:
16
11
2022
medline:
31
3
2023
pubmed:
28
12
2022
entrez:
27
12
2022
Statut:
ppublish
Résumé
The 25 hydroxyvitamin D [25(OH)D] is the major metabolite for ascertaining vitamin D status, which circulates bound to a specific carrier (vitamin D-binding protein - VDBP). A portion that circulates unbound vary according to the VDBP genotype. This study evaluates the behavior of different forms of 25(OH)D, before and after supplementation with 14,000 IU of vitamin D3, weekly for 12 weeks, in individuals with primary hyperparathyroidism and controls. Fifty-six patients with active primary hyperparathyroidism (PHPT) and 64 paired controls (CTRL), not taking vitamin D3 for the last three months, were enrolled. The genetic isotypes of VDBP were determined to calculate bioavailable and free 25(OH)D. A p < 0.05 was considered significant. There were no statistical differences in free, bioavailable, and total 25(OH)D levels between PHPT and CTRL groups at baseline. The distribution of VDBP haplotypes 1s/1s, 1f/1f, 1s/1f, 2/2, 1s/2, and 1f/2 was similar between groups. After supplementation, all three forms of 25(OH)D proportionally increased within each group, although the percentage increment was lower in the PHPT group (p < 0.05). Total 25(OH)D is better correlated with PTH in the PHPT group than bioavailable and free 25(OH)D (r = -0.41; p < 0.05). The concentrations of total, free, and bioavailable 25(OH)D were similar in both PHPT and CTRL groups, and all forms increased proportionally after supplementation, although this increment percentage was higher in the CTRL group, with a subsequent reduction of PTH and AP. Total 25(OH)D correlated better with PTH than other forms, suggesting no advantages in measuring free or bioavailable 25(OH)D in these situations.
Identifiants
pubmed: 36574149
doi: 10.1007/s12020-022-03265-8
pii: 10.1007/s12020-022-03265-8
doi:
Substances chimiques
Cholecalciferol
1C6V77QF41
25-hydroxyvitamin D
A288AR3C9H
Vitamin D
1406-16-2
Vitamin D-Binding Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-190Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
S.-W. Chang, H.-C. Lee, Vitamin D and health - The missing vitamin in humans. Pediatr. Neonatol. 60, 237–244 (2019)
doi: 10.1016/j.pedneo.2019.04.007
pubmed: 31101452
M.L. Kottler, K.P. Schlingmann, Genetic diseases of vitamin D metabolizing enzymes. Endocrinology. (2017). https://www.endo.theclinics.com/article/S0889-8529(17)30073-7/abstract
J.A. Eisman, R.M. Shepard, H.F. DeLuca, Determination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in human plasma using high-pressure liquid chromatography. Anal. Biochem. 80, 298–305 (1977)
doi: 10.1016/0003-2697(77)90648-0
pubmed: 883638
F. Bienaimé, D. Prié, G. Friedlander, J.C. Souberbielle, Vitamin D metabolism and activity in the parathyroid gland. Mol. Cell Endocrinol. 347, 30–41 (2011)
doi: 10.1016/j.mce.2011.05.031
pubmed: 21664247
J. Silver, J. Russell, L.M. Sherwood, Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc. Natl Acad. Sci. 82, 4270–4273 (1985)
doi: 10.1073/pnas.82.12.4270
pubmed: 3858880
pmcid: 397979
D.D. Bikle, J. Schwartz, Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions. Front Endocrinol. (2019). https://doi.org/10.3389/fendo.2019.00317
R. Takiar, P.L. Lutsey, D. Zhao, E. Guallar, A.L.C. Schneider, M.E. Grams et al. The associations of 25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms, and race with risk of incident fracture-related hospitalization: Twenty-year follow-up in a bi-ethnic cohort (the ARIC Study). Bone 78, 94–101 (2015)
doi: 10.1016/j.bone.2015.04.029
pubmed: 25920689
pmcid: 4466148
M.D. Walker, K.K. Nishiyama, B. Zhou, E. Cong, J. Wang, J.A. Lee et al. Effect of Low Vitamin D on Volumetric Bone Mineral Density, Bone Microarchitecture, and Stiffness in Primary Hyperparathyroidism. J. Clin. Endocrinol. Metab. 101, 905–913 (2016)
doi: 10.1210/jc.2015-4218
pubmed: 26745256
pmcid: 4803169
P. Boudou, F. Ibrahim, C. Cormier, E. Sarfati, J.C. Souberbielle, A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J. Endocrinol. Investig. 29, 511–515 (2006)
doi: 10.1007/BF03344140
B. Moosgaard, P. Vestergaard, L. Heickendorff, F. Melsen, P. Christiansen, L. Mosekilde, Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin. Endocrinol. 63, 506–513 (2005)
doi: 10.1111/j.1365-2265.2005.02371.x
D.S. Rao, M. Honasoge, G.W. Divine, E.R. Phillips, M.W. Lee, M.R. Ansari et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J. Clin. Endocrinol. Metab. 85, 1054–1058 (2000)
pubmed: 10720039
D.S. Rao, G. Agarwal, G.B. Talpos, E.R. Phillips, F. Bandeira, S.K. Mishra et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J. Bone Min. Res. 17, N75–N80 (2002)
B. Moosgaard, P. Vestergaard, L. Heickendorff, F. Melsen, P. Christiansen, L. Mosekilde, Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol. 155, 237–244 (2006)
doi: 10.1530/eje.1.02197
pubmed: 16868136
S.S. Maeda, G.L. Saraiva, L.F. Hayashi, M.S. Cendoroglo, L.R. Ramos, M. Corrêa, P. de et al. Seasonal variation in the serum 25-hydroxyvitamin D levels of young and elderly active and inactive adults in São Paulo, Brazil: The São PAulo Vitamin D Evaluation Study (SPADES). Dermatoendocrinol 5, 211–217 (2013)
doi: 10.4161/derm.24476
pubmed: 24494057
pmcid: 3897593
B.N. Fitzpatrick, Fitzpatrick tongue guard/retractors. Br. J. Oral. Surg. 16, 274 (1979)
doi: 10.1016/0007-117X(79)90035-0
pubmed: 285730
C.M. Henderson, P.L. Lutsey, J.R. Misialek, T.J. Laha, E. Selvin, J.H. Eckfeldt et al. Measurement by a Novel LC-MS/MS Methodology Reveals Similar Serum Concentrations of Vitamin D-Binding Protein in Blacks and Whites. Clin. Chem. 62, 179–187 (2016)
doi: 10.1373/clinchem.2015.244541
pubmed: 26453697
M.R. Denburg, A.N. Hoofnagle, S. Sayed, J. Gupta, I.H. de Boer, L.J. Appel et al. Comparison of Two ELISA Methods and Mass Spectrometry for Measurement of Vitamin D-Binding Protein: Implications for the Assessment of Bioavailable Vitamin D Concentrations Across Genotypes. J. Bone Min. Res. 31, 1128–1136 (2016)
doi: 10.1002/jbmr.2829
M.M.L. Kizys, M.G. Cardoso, S.C. Lindsey, M.Y. Harada, F.A. Soares, M.C.C. Melo et al. Optimizing nucleic acid extraction from thyroid fine-needle aspiration cells in stained slides, formalin-fixed/paraffin-embedded tissues, and long-term stored blood samples. Arq. Bras. Endocrinol. Metab. 56, 618–626 (2012)
doi: 10.1590/S0004-27302012000900004
J. Arnaud, J. Constans, Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum. Genet 92, 183–188 (1993)
doi: 10.1007/BF00219689
pubmed: 8370586
D.D. Bikle, E. Gee, B. Halloran, M.A. Kowalski, E. Ryzen, J.G. Haddad, Assessment of the Free Fraction of 25-Hydroxyvitamin D in Serum and Its Regulation by Albumin and the Vitamin D-Binding Protein *. J Clin Endocrinol Metab. (1986). https://doi.org/10.1210/jcem-63-4-954
C. Battista, V. Guarnieri, V. Carnevale, F. Baorda, M. Pileri, M. Garrubba et al. Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine 55, 266–272 (2017)
doi: 10.1007/s12020-016-0974-x
pubmed: 27154872
L. Meng, S. Liu, A. Al-Dayyeni, Z. Sheng, Z. Zhou, X. Wang, Comparison of Initial Clinical Presentations between Primary Hyperparathyroidism Patients from New Brunswick and Changsha. Int J. Endocrinol. 2018, 6282687 (2018)
doi: 10.1155/2018/6282687
pubmed: 30363962
pmcid: 6186333
I. Bhan, Vitamin d binding protein and bone health. Int J. Endocrinol. 2014, 561214 (2014)
doi: 10.1155/2014/561214
pubmed: 24987416
pmcid: 4058579
R. Bouillon, F. Schuit, L. Antonio, F. Rastinejad, Vitamin D Binding Protein: A Historic Overview. Front Endocrinol. 10, 910 (2019)
doi: 10.3389/fendo.2019.00910
K.C. Norris, S.F. Williams, Race/Ethnicity, Serum 25-Hydroxyvitamin D, and Heart Disease. JAMA 310, 153–155 (2013)
doi: 10.1001/jama.2013.7229
pubmed: 23839748
pmcid: 5043406
B.R. Santos, N.C. Costa, T.R. Silva, K. Oppermann, J.A. Magalhães, G. Casanova et al. Prevalence of vitamin D deficiency in women from southern Brazil and association with vitamin D-binding protein levels and GC-DBP gene polymorphisms. PLoS One. 14, e0226215 (2019)
doi: 10.1371/journal.pone.0226215
pubmed: 31830090
pmcid: 6907813
G. Viccica, F. Cetani, E. Vignali, M. Miccoli, C. Marcocci, Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine 55, 256–265 (2017)
doi: 10.1007/s12020-016-0931-8
pubmed: 27033542
W. Rankin, Primary hyperparathyroidism - is vitamin D supplementation safe? Aust. Fam. Physician. 40, 881–884 (2011)
pubmed: 22059217
V.N. Shah, C.S. Shah, S.K. Bhadada, D.S. Rao, Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin. Endocrinol. 80, 797–803 (2014)
doi: 10.1111/cen.12398
X. Wang, S.A. Shapses, S. Wei, D. Sukumar, J. Ghosh, Vitamin D-binding protein levels in female patients with primary hyperparathyroidism. Endocr. Pr. 19, 609–613 (2013)
doi: 10.4158/EP12371.OR
D.D. Bikle, B.P. Halloran, E. Gee, E. Ryzen, J.G. Haddad, Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. J Clin Investig. 748–752 (1986). https://doi.org/10.1172/jci112636
L.C Pop, S.A. Shapses, B.Chang, W.Sun, X.Wang. Vitamin d-binding protein in healthy pre- and postmenopausal women: relationship with estradiol concentrations. Endocrine Practice. 2015 936–942 (2015). https://doi.org/10.4158/ep15623.or
M.R. Bennett, A. Pordal, C. Haffner, L. Pleasant, Q. Ma, P. Devarajan, Urinary Vitamin D-Binding Protein as a Biomarker of Steroid-Resistant Nephrotic Syndrome. Biomark. Insights. 11, 1–6 (2016)
doi: 10.4137/BMI.S31633
pubmed: 26792978
pmcid: 4712977
X. Wang, S.A. Shapses, H. Al-Hraishawi, Free and bioavailable 25-hydroxyvitamin d levels in patients with primary hyperparathyroidism. Endocr. Pr. 23, 66–71 (2017)
doi: 10.4158/EP161434.OR
X. Wang, Z.Sheng, L. Meng, C.Su, S.Trooskin, S.A. Shapses. 25-Hydroxyvitamin D and Vitamin D Binding Protein Levels in Patients With Primary Hyperparathyroidism Before and After Parathyroidectomy. Front. Endocrnol. 2019. https://doi.org/10.3389/fendo.2019.00171
L. Rolighed, L. Rejnmark, T. Sikjaer, L. Heickendorff, P. Vestergaard, L. Mosekilde et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 99, 1072–1080 (2014)
doi: 10.1210/jc.2013-3978
pubmed: 24423366